Bifogade filer
Lytix - Saturn Invest AS - Mandatory notification of trade
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-12-17 15:53:15
Oslo, Norway, 17 December 2024: Reference is made to the stock exchange
announcement published by Lytix Biopharma AS ("Lytix" or the "Company") earlier
today, on 17 December 2024, regarding the successful completion of a private
placement (the "Private Placement") of new shares raising NOK 100 million in
gross proceeds, and a retail offering (the "PrimaryBid Offering") of new shares
raising NOK 11.3 million in gross proceeds via the PrimaryBid platform.
As part of the settlement arrangements for the Private Placement and the
PrimaryBid Offering, the Company has entered into a share lending agreement (the
"Share Lending Agreement") with certain existing shareholders, including Saturn
Invest AS ("Saturn Invest"), and the joint bookrunners of the Private Placement,
Carnegie AS and DNB Markets, a part of DNB Bank ASA (the "Managers"). The share
loan will be settled with new shares in the Company resolved issued by board of
directors, as further described in the stock exchange announcement published
earlier today regarding the completion of the Private Placement and the
PrimaryBid Offering.
Pursuant to the Share Lending Agreement and for the purposes stated above, the
close associate to a primary insider, Saturn Invest, has lent out 1,318,913
shares to Carnegie AS (on behalf of the Managers). Please see the attached form
for more information.
Disclosure regulation:
This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.
For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com
Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.